SML3342
Trofinetide Trifluoroacetate
≥95% (HPLC)
别名:
Gly-2–methylPro–Glu Trifluoroacetate, Gly-2MePro-Glu Trifluoroacetate, Glycyl-2-methyl-L-prolyl-L-Glutamic acid Trifluoroacetate, NNZ 2566 Trifluoroacetate, NNZ-2566 Trifluoroacetate
登录查看公司和协议定价
所有图片(1)
About This Item
经验公式（希尔记法）:
C13H21N3O6 · xC2HF3O2
分子量:
315.32 (free base basis)
UNSPSC代码:
51111800
NACRES:
NA.77
推荐产品
生化/生理作用
Enzymatically stable analogue of the N-terminal tripeptide of IGF-1(GPE) that exhibits potent neuroprotective effects in varies animal models.
Trofinetide is a more enzymatically stable analogue of the N-terminal tripeptide of IGF-1(GPE) that exhibits potent neuroprotective effects in varies animal models of neurodegenerative diseases and traumatic brain injury. Trofinetide treatment provides clinically meaningful improvement in Rett syndrome (RTT) and Fragile X syndrome (FXS).
储存分类代码
11 - Combustible Solids
WGK
WGK 3
法规信息
新产品
历史批次信息供参考:
分析证书(COA)
Lot/Batch Number
NNZ-2566: a Gly-Pro-Glu analogue with neuroprotective efficacy in a rat model of acute focal stroke.
Michael J Bickerdike et al.
Journal of the neurological sciences, 278(1-2), 85-90 (2009-01-23)
The N-terminal cleavage product of human insulin-like growth factor-1 (IGF-1) in the brain is the tripeptide molecule Glypromate (Gly-Pro-Glu). Glypromate has demonstrated neuroprotective effects in numerous in vitro and in vivo models of brain injury and is in clinical trials
Casandra M Cartagena et al.
Neuromolecular medicine, 15(3), 504-514 (2013-06-15)
The tripeptide glycine-proline-glutamate analogue NNZ-2566 (Neuren Pharmaceuticals) demonstrates neuroprotective efficacy in models of traumatic brain injury. In penetrating ballistic-like brain injury (PBBI), it significantly decreases injury-induced upregulation of inflammatory cytokines including TNF-α, IFN-γ, and IL-6. However, the mechanism by which
Elizabeth Berry-Kravis et al.
Pediatric neurology, 110, 30-41 (2020-07-15)
We analyze the safety and tolerability of trofinetide and provide a preliminary evaluation of its efficacy in adolescent and adult males with fragile X syndrome. This study was an exploratory, phase 2, multicenter, double-blind, placebo-controlled, parallel group study of the
我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系技术服务部门